This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Practice Guideline

. 2012 Oct:23 Suppl 7:vii110-9.

doi: 10.1093/annonc/mds230.

Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

F Pacini¹, M G Castagna, L Brilli, G Pentheroudakis; ESMO Guidelines Working Group

Affiliations

PMID: 22997443
DOI: 10.1093/annonc/mds230

Free article

Practice Guideline

Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

F Pacini et al. Ann Oncol. 2012 Oct.

Free article

. 2012 Oct:23 Suppl 7:vii110-9.

doi: 10.1093/annonc/mds230.

Authors

F Pacini¹, M G Castagna, L Brilli, G Pentheroudakis; ESMO Guidelines Working Group

Affiliation

¹ Department of Internal Medicine, Section of Endocrinology and Metabolism, University of Siena, Sienna, Italy.

PMID: 22997443
DOI: 10.1093/annonc/mds230

No abstract available

PubMed Disclaimer

Similar articles

Contemporary management of papillary carcinoma of the thyroid gland.
Rosenbaum MA, McHenry CR. Rosenbaum MA, et al. Expert Rev Anticancer Ther. 2009 Mar;9(3):317-29. doi: 10.1586/14737140.9.3.317. Expert Rev Anticancer Ther. 2009. PMID: 19275510 Review.
[Diagnosis and therapy of differentiated thyroid gland carcinomas].
Mann K. Mann K. Internist (Berl). 2002 Feb;43(2):174-85. doi: 10.1007/s00108-001-0526-0. Internist (Berl). 2002. PMID: 11963755 Review. German. No abstract available.
Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Fallahi P, Ferrari SM, Galdiero MR, Varricchi G, Elia G, Ragusa F, Paparo SR, Benvenga S, Antonelli A. Fallahi P, et al. Semin Cancer Biol. 2022 Feb;79:180-196. doi: 10.1016/j.semcancer.2020.11.013. Epub 2020 Nov 26. Semin Cancer Biol. 2022. PMID: 33249201 Review.
[Diagnosis and treatment of differentiated thyroid carcinoma].
Mora J. Mora J. Rev Esp Med Nucl. 2003 Sep-Oct;22(5):349-59; quiz 360-2. doi: 10.1016/s0212-6982(03)72215-0. Rev Esp Med Nucl. 2003. PMID: 14534014 Review. Spanish. No abstract available.
Management of microcarcinomas (papillary and medullary) of the thyroid.
Wu LS, Milan SA. Wu LS, et al. Curr Opin Oncol. 2013 Jan;25(1):27-32. doi: 10.1097/CCO.0b013e328359feea. Curr Opin Oncol. 2013. PMID: 23042124 Review.

See all similar articles

Cited by

A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.
Cabanillas ME, Schlumberger M, Jarzab B, Martins RG, Pacini F, Robinson B, McCaffrey JC, Shah MH, Bodenner DL, Topliss D, Andresen C, O'Brien JP, Ren M, Funahashi Y, Allison R, Elisei R, Newbold K, Licitra LF, Sherman SI, Ball DW. Cabanillas ME, et al. Cancer. 2015 Aug 15;121(16):2749-56. doi: 10.1002/cncr.29395. Epub 2015 Apr 24. Cancer. 2015. PMID: 25913680 Free PMC article. Clinical Trial.
Thyroid cancer in women of reproductive age: Key issues for the clinical team.
Toro-Wills MF, Imitola-Madero A, Alvarez-Londoño A, Hernández-Blanquisett A, Martínez-Ávila MC. Toro-Wills MF, et al. Womens Health (Lond). 2022 Jan-Dec;18:17455057221136392. doi: 10.1177/17455057221136392. Womens Health (Lond). 2022. PMID: 36373610 Free PMC article. Review.
Impact of combined FDG-PET/CT and MRI on the detection of local recurrence and nodal metastases in thyroid cancer.
Hempel JM, Kloeckner R, Krick S, Pinto Dos Santos D, Schadmand-Fischer S, Boeßert P, Bisdas S, Weber MM, Fottner C, Musholt TJ, Schreckenberger M, Miederer M. Hempel JM, et al. Cancer Imaging. 2016 Nov 3;16(1):37. doi: 10.1186/s40644-016-0096-y. Cancer Imaging. 2016. PMID: 27809936 Free PMC article.
Calcium-stimulated calcitonin - The "new standard" in the diagnosis of thyroid C-cell disease - clinically relevant gender-specific cut-off levels for an "old test".
Niederle MB, Scheuba C, Gessl A, Li S, Koperek O, Bieglmayer C, Riss P, Selberherr A, Niederle B. Niederle MB, et al. Biochem Med (Zagreb). 2018 Oct 15;28(3):030710. doi: 10.11613/BM.2018.030710. Biochem Med (Zagreb). 2018. PMID: 30429678 Free PMC article.
IGF2 is a potential factor in RAI-refractory differentiated thyroid cancer.
Crezee T, Tesselaar MH, Jaeger M, Rabold K, Corver WE, Morreau H, Van Engen-Van Grunsven ACH, Smit JWA, Netea-Maier RT, Plantinga TS. Crezee T, et al. Oncol Lett. 2021 Aug;22(2):590. doi: 10.3892/ol.2021.12851. Epub 2021 Jun 6. Oncol Lett. 2021. PMID: 34149901 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information